title: [Acute renal failure - anticoagulation in continuous renal replacement therapy].
abstract: Anticoagulation plays a pivotal role for the efficacy of continuous renal replacement therapy. The equilibrium between avoiding bleeding complications and keeping the system open considering patients} multiple diseases demands an individual and dynamic reasoned anticoagulation regime. For patients at risk of bleeding citrate anticoagulation has shown high efficacy and lesser bleeding complications than the standard heparin or other alternative anticoagulants such as regional protamin-heparin-, prostaglandin-heparin-anticoagulation or no anticoagulation.
authors.affiliation: Klinik für Anästhesiologie und operative Intensivmedizin, Campus Virchow-Klinikum und Campus Charité Mitte, Charité - Universitätsmedizin Berlin. ortrud.vargas@charite.de
authors.forename: Ortrud Vargas
authors.initials: OV
authors.lastname: Hein
authors.forename: Jürgen
authors.initials: J
authors.lastname: Birnbaum
authors.forename: Claudia
authors.initials: C
authors.lastname: Spies
mesh_terms: D058186:Acute Kidney Injury / Q000628:therapy*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001780:Blood Coagulation Tests; D002951:Citrates / Q000008:administration & dosage / Q000009:adverse effects; D003422:Critical Care / Q000379:methods*; D003546:Cysteine Endopeptidases; D004305:Dose-Response Relationship, Drug; D006440:Hemofiltration / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010314:Partial Thromboplastin Time; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects; D011479:Protamines / Q000008:administration & dosage / Q000009:adverse effects; D000077559:Sodium Citrate
chemical_list: D000925:Anticoagulants; D002951:Citrates; D006495:Heparin, Low-Molecular-Weight; D009363:Neoplasm Proteins; D011453:Prostaglandins; D011479:Protamines; C030101:protamine heparin aggregate; D000077559:Sodium Citrate; D006493:Heparin; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant